CHEMICON International And Thromb-X, NV Enter Into Agreement For Exclusive Sale And Marketing Of New Embryonic Stem Cell Tissue Culture Media 
10/19/2005 5:11:57 PM

Thromb-X N.V., the R&D division of ThromboGenics Ltd., and Chemicon International, a division of Serologicals Corporation (NASDAQ/NM: SERO), today announced the signing of an exclusive global agreement to market embryonic stem (ES) cell reagents developed by Thromb-X. The centerpiece of this agreement is the commercialization of the TX-WES culture medium that was specifically developed to enable the derivation of new "non-permissive" strains and to rescue existing ES cell lines.